Switch to
More onapp

How to use scorecard? Learn more

Marksans Pharma Ltd

MARKSANS
Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,103 cr, stock is ranked 460
High RiskStock is 3.96x as volatile as Nifty
289.152.30 (+0.80%)

Price Chart

High
Low
Returns
1D
1W
1M
1Y
5Y
Max
SIP
Loading...
1D
1W
1M
1Y
5Y
Max
SIP
Scorecard

Performance

High

The creamy layer - amongst the top performing stocks

Valuation

High

Seems to be overvalued vs the market average

Growth

Low

Lagging behind the market in financials growth

Profitability

High

Showing good signs of profitability & efficiency

Entry point

Avg

The stock is overpriced but is not in the overbought zone

Red flags

Low

No red flag found

How to use scorecard? Learn more

Health CarePharmaceuticals
SmallcapWith a market cap of ₹13,103 cr, stock is ranked 460
High RiskStock is 3.96x as volatile as Nifty

Key MetricsEdit

No LabelNo Label
39.25
PB RatioPB Ratio
6.28
Dividend YieldDiv. Yield
Sector PESector PE
52.29
Sector PBSector PB
6.68
Sector Div YldSctr Div Yld
0.47%

Forecast & RatingsDetailed Forecast 

100%

Analysts have suggested that investors can buy this stock

Price

Price Upside

Pro Only

Earnings

Earnings Growth

Pro Only

Revenue

Rev. Growth

Pro Only

See Detailed Forecast

Company Profile

Marksans Pharma Limited is a pharmaceutical company, which is engaged in the research, manufacturing and marketing of generic pharmaceutical formulations.

Financial TrendFinancial statements 

20212022202320241.381.531.912.230.240.180.270.31
Revenue
Profit
All values in ₹ Thousand cr.
See financial statements

Holdings TrendDetailed holdings 

Total Promoter Holding
Increasing promoter holding is considered good and reflects management’s positive view about the future outlook

In last 6 months, promoter holding in the company has almost stayed constant

Low Pledged Promoter Holding
Lower pledged promoter holdings is considered better

Pledged promoter holdings is insignificant

Decreased Mutual Fund Holding
Increasing Mutual Fund holdings are generally considered good, as it reflects that fund managers are becoming more bullish about the stock

In last 3 months, mutual fund holding of the company has decreased by 1.41%

See detailed holdings

Recent NewsAll news 

Hmm, looks like data is unavailable here. Please come back after some time
See all news

Recent EventsAll events 

Certificate under SEBI (Depositories and Participants) Regulations, 2018 
Announced OnOct 9, 2024

Marksans Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Download

Marksans Pharma Limited has informed the Exchange about Certificate under SEBI (Depositories and Participants) Regulations, 2018 | Download

Trading Window-XBRL 
Announced OnSep 27, 2024

MARKSANS PHARMA LIMITED has informed the Exchange about Closure of Trading Window | Download

MARKSANS PHARMA LIMITED has informed the Exchange about Closure of Trading Window | Download

Cash Dividend 
Ex. DateSep 17, 2024

Final • Div/Share: ₹ 0.6

See all events